Decreased Expression of microRNA‑214 Contributes to Imatinib Mesylate Resistance of Chronic Myeloid Leukemia Patients by Upregulating ABCB1 Gene Expression

Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2018.6404
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

Hematology Reports
Hematology
2012English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

Cyr61 Regulates the Chemosensitivity of Chronic Myeloid Leukemia to Imatinib Mesylate Through the NF ‐κB/Bcl‐2 Pathway

Cancer Science
Cancer ResearchMedicineOncology
2019English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy